The language of this new and latest notice, you may need to 'login' to their web site to read it, suggests that more than fifty percent of newly diagnosed ALS patients are likely eligible for DPS, whereas other notices have either not articulated an estimate or offered an estimate that implied only about ten percent of new cases are probably eligible.
Medscape: Medscape Access
"Of 5600 new cases diagnosed each year, an estimated subset of 3300 patients with both respiratory failure and an intact phrenic nerve could benefit from this therapy, the company statement notes."
Ah, Ha! The company has a lengthy (PDF) news release related to the FDA approval here:
Synapse :: News :: Media Center
There is even an brief explanatory video on their web site:
Synapse :: Media Center :: How the NeuRx DPS™ Works
Medscape: Medscape Access
"Of 5600 new cases diagnosed each year, an estimated subset of 3300 patients with both respiratory failure and an intact phrenic nerve could benefit from this therapy, the company statement notes."
Ah, Ha! The company has a lengthy (PDF) news release related to the FDA approval here:
Synapse :: News :: Media Center
There is even an brief explanatory video on their web site:
Synapse :: Media Center :: How the NeuRx DPS™ Works